Neurotech International Limited has been informed that the first patient has received treatment in the Phase I/II clinical trial of NTI164 in children diagnosed with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Recruitment of the 15 patients is now anticipated to complete during First Quarter 2023, with results of the trial anticipated in second half of calendar year 2023. The trial is now open for enrollment at two centres within Australia; the Children's Hospital at Westmead and the Paediatric Neurology Unit at Monash Medical Centre.

The Phase I/II clinical trial has been registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number: ACTRN126220-01419752.